Botulinum Neurotoxins Type A &B: A Comparative Cross-Sectional Study of Mechanism, Efficacy, and Clinical Applications

Abstract Background Botulinum toxin type A and type B are widely used in cosmetic and medical practice due to their neuromuscular blocking properties. Although both toxins share a similar mechanism of action, differences in pharmacological characteristics have raised questions regarding their comparative efficacy, safety, and clinical applications. Direct comparative data across multiple outcome measures remain limited. Objective This study aimed to compare the clinical efficacy and safety of botulinum toxin type A and type B in cosmetic and medical indications, and to assess whether statistically significant differences exist between the two types with respect to adverse effects, severity of improvement, patient satisfaction, duration of effect, time to onset, and type of diagnosis. Methods A comparative cross-sectional study was conducted involving 126 patients who received either botulinum toxin type A or type B injections for cosmetic or medical purposes. Data were collected using a structured electronic questionnaire and included demographic variables, clinical outcomes, adverse effects, satisfaction levels, duration and onset of effect, and indication type. Statistical analysis was performed using descriptive statistics, chi-square tests, and Fisher’s exact tests where appropriate. Statistical significance was set at P < 0.05. Results No statistically significant differences were observed between botulinum toxin type A and type B in terms of incidence or severity of adverse effects, degree of clinical improvement, overall patient satisfaction, duration of effect, time to onset, or diagnostic use (cosmetic versus medical). Both toxin types demonstrated comparable efficacy and safety profiles across all evaluated parameters. Conclusion Botulinum toxin type A and type B exhibit a high degree of clinical equivalence in terms of efficacy, safety, and patient-reported outcomes in both cosmetic and medical applications. The choice between the two toxins should therefore be guided by clinical context, practitioner experience, availability, and individual patient factors rather than expectations of substantial differences in therapeutic performance.